Ligand Pharmaceuticals Incorporated Financials

Market Capitalization $2.22 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	47.13
Forward PE	19.63
Price to Sales TTM	$14.55
Price to Book MRQ	$2.62
Enterprise to Revenue	13.16
Enterprise to EBITDA	38.10

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	29.68%
Operating Margin	21.14%
Return on Assets TTM	1.30%
Return on Equity TTM	6.00%

Income Statement

Revenue TTM	$152,422,000
Revenue per Share TTM	$8.51
Quarterly Revenue Growth	57.60%
Gross Profit TTM	$120,056,000
EBITDA	$51,223,000
Net Income to Common TTM	$45,244,000
Diluted EPS TTM	$2.49
Quarterly Earnings Growth YoY	57.64%

Balance Sheet

Total Cash MRQ	$219,643,008
Total Cash per Share MRQ	$11.62
Total Debt MRQ	$
Total Debt to Equity MRQ	0.88
Current Ratio MRQ	12.49
Book Value per Share MRQ	$44.84

Cash Flow

Operating Cash Flow TTM	$76,641,000
Levered Free Cash Flow TTM	$16,959,876

LGND Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	18,895,400
Float Shares	18,519,355
Avg 10 Volume	96,010
Avg 30 Volume	None
Shares Short	900,125
Short Ratio	6.84
Short % of Shares	6.59%
% Held by Insiders	1.87%
% Held by Institutions	100.77%

Stock Price Summary

Beta	0.90
Fifty Two Week Low	$67.72
Fifty Two Week High	$129.90
Fifty Two Week Change	34.75%
Day 50 MA	$115.75
Day 200 MA	$98.94

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2010-07-02
Last Split Factor
Last Split Date	2022-11-02